Dual kinase-bromodomain inhibitors for rationally designed polypharmacology

Concomitant inhibition of multiple cancer-driving kinases is an established strategy to improve the durability of clinical responses to targeted therapies. The difficulty of discovering kinase inhibitors with an appropriate multi-target profile has, however, necessitated the application of combinati...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciceri, Pietro, Müller, Susanne, O’Mahony, Alison, Fedorov, Oleg, Filippakopoulos, Panagis, Hunt, Jeremy P., Lasater, Elisabeth A., Pallares, Gabriel, Picaud, Sarah, Wells, Christopher, Martin, Sarah, Wodicka, Lisa M., Shah, Neil P., Treiber, Daniel K., Knapp, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3998711/
https://www.ncbi.nlm.nih.gov/pubmed/24584101
http://dx.doi.org/10.1038/nchembio.1471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3998711/
https://www.ncbi.nlm.nih.gov/pubmed/24584101
http://dx.doi.org/10.1038/nchembio.1471

Ejemplares similares